Main content
Efficacy, immunogenicity and harms of SARS-CoV-2 booster vaccination for kidney transplant recipients: a systematic review
- Renate Hausinger
- Quirin Bachmann
- Timotius Crone-Rawe
- Nora Hannane
- Christoph Schmaderer
- Nina Kreuzberger
- Nicole Skoetz
- Ina Monsef
Date created: | Last Updated:
: DOI | ARK
Creating DOI. Please wait...
Category: Project
Description: The aim of this systematic review is to synthetize evidence for the immune response to additional doses of SARS-CoV-2- vaccines after full immunization and vaccine efficacy. Adverse events, especially concerning de-novo-formation of donor-specific antibodies and acute graft rejections will also be reported. We will include analyses of the vaccines appproved for emergency use by the EMA and also by the WHO. In addition, we will include Sputnik V (Gamaleya Gam-COVID-Vac vaccine) despite pending approval by EMA or WHO because of its wide distribution in 74 countries as of February 14th. - Cominarty (BioNTech and Pfizer), also Tozinameran, BNT162b2 - Nuvaxovid (Novavax), also NVX-CoV2373 and their formulations - Spikevax (Moderna), also mRNA-1273 - Vaxzevria (Oxford/AstraZeneca), also AZD1222, ChAdOx1 nCoV-19 and their formulations - COVID-19 Vaccine Janssen (Johnson & Johnson), also Ad26COVS1, JNJ-78436735 - Sinovac, also Coronavac - Covilo (Sinopharm (Beijing)), also BBIBP-CorV (Vero Cells) - Covaxin (Bharat Biotech), also BBV152
Start managing your projects on the OSF today.
Free and easy to use, the Open Science Framework supports the entire research lifecycle: planning, execution, reporting, archiving, and discovery.